Mometasona Gsp (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasona Gsp, is a corticosteroid presented as a nasal spray for nasal use. It treats inflammatory nasal conditions such as allergic rhinitis and nasal polyps in adults and children.

GNH USA supplies Mometasona Gsp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray acts on inflammatory pathways of the nasal mucosa to relieve symptoms of several nasal disorders. - Allergic rhinitis: Reduces nasal congestion, itching, sneezing and rhinorrhea associated with seasonal or perennial allergies. - Non‑allergic rhinitis: Improves nasal airflow and decreases irritation caused by non‑allergic triggers. - Nasal polyps: Shrinks polyp size and alleviates obstruction, improving breathing and sense of smell.

Mometasone furoate nasal spray may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Epistaxis (nosebleed) - Throat irritation or dryness - Altered taste or bitter taste - Cough

Serious or Rare Side Effects: - Nasal septal perforation - Severe or prolonged epistaxis - Visual disturbances (e.g., cataracts, glaucoma) - Adrenal suppression with prolonged high‑dose use - Opportunistic fungal infection of the nasal passages - Systemic corticosteroid effects such as hyperglycemia

Before initiating therapy, consider the following safety measures. - Assess for active nasal infection: Avoid use if bacterial, viral, or fungal infection is present. - Evaluate history of glaucoma or cataracts: Monitor intra‑ocular pressure during treatment. - Review systemic corticosteroid use: Minimize combined systemic exposure. - Counsel patients on proper spray technique to reduce local irritation. - Store at ambient temperature: Keep below 25°C in the original container, protect from moisture and direct sunlight.

Mometasone furoate may interact with other medications that affect corticosteroid metabolism or increase systemic exposure.

Major Interactions (Avoid): - Concurrent use of other intranasal corticosteroids: Increases risk of local and systemic side effects. - Systemic glucocorticoids: Potentiates systemic corticosteroid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May raise systemic mometasone levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): May modestly increase exposure. - Antifungal azoles used systemically: Monitor for signs of adrenal suppression. - Ritonavir or other protease inhibitors: Observe for enhanced systemic effects.